Novocure Ltd (NVCR) Director Sells $241,550.00 in Stock

Novocure Ltd (NASDAQ:NVCR) Director Gabriel Leung sold 5,000 shares of Novocure stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $48.31, for a total value of $241,550.00. Following the sale, the director now owns 65,000 shares of the company’s stock, valued at approximately $3,140,150. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Gabriel Leung also recently made the following trade(s):

  • On Friday, March 1st, Gabriel Leung sold 25,000 shares of Novocure stock. The stock was sold at an average price of $55.01, for a total value of $1,375,250.00.
  • On Monday, February 11th, Gabriel Leung sold 5,000 shares of Novocure stock. The stock was sold at an average price of $49.59, for a total value of $247,950.00.
  • On Friday, January 25th, Gabriel Leung sold 20,000 shares of Novocure stock. The stock was sold at an average price of $50.00, for a total value of $1,000,000.00.
  • On Wednesday, January 16th, Gabriel Leung sold 20,000 shares of Novocure stock. The stock was sold at an average price of $45.00, for a total value of $900,000.00.
  • On Wednesday, January 9th, Gabriel Leung sold 20,000 shares of Novocure stock. The stock was sold at an average price of $40.00, for a total value of $800,000.00.

NVCR opened at $51.43 on Friday. The company has a debt-to-equity ratio of 1.33, a current ratio of 4.98 and a quick ratio of 4.63. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of -73.47 and a beta of 3.24. Novocure Ltd has a 12 month low of $19.55 and a 12 month high of $56.67.



Novocure (NASDAQ:NVCR) last posted its quarterly earnings results on Thursday, February 28th. The medical equipment provider reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). Novocure had a negative net margin of 25.62% and a negative return on equity of 57.09%. As a group, sell-side analysts forecast that Novocure Ltd will post -0.67 EPS for the current fiscal year.

Several research firms have commented on NVCR. Wells Fargo & Co restated a “hold” rating on shares of Novocure in a report on Thursday, February 28th. Zacks Investment Research upgraded Novocure from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. BidaskClub upgraded Novocure from a “buy” rating to a “strong-buy” rating in a report on Friday, January 25th. Finally, Mizuho restated a “buy” rating and issued a $63.00 price target on shares of Novocure in a report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $49.71.

A number of institutional investors and hedge funds have recently bought and sold shares of NVCR. Dimensional Fund Advisors LP acquired a new position in shares of Novocure in the 3rd quarter valued at about $1,323,000. Credit Suisse AG lifted its stake in shares of Novocure by 87.2% in the 3rd quarter. Credit Suisse AG now owns 945,654 shares of the medical equipment provider’s stock valued at $49,552,000 after purchasing an additional 440,543 shares in the last quarter. FMR LLC lifted its stake in shares of Novocure by 37.9% in the 3rd quarter. FMR LLC now owns 10,845,246 shares of the medical equipment provider’s stock valued at $568,292,000 after purchasing an additional 2,983,125 shares in the last quarter. First Republic Investment Management Inc. acquired a new position in shares of Novocure in the 3rd quarter valued at about $1,609,000. Finally, Rhenman & Partners Asset Management AB lifted its stake in shares of Novocure by 36.3% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 545,000 shares of the medical equipment provider’s stock valued at $18,247,000 after purchasing an additional 145,000 shares in the last quarter. Institutional investors own 61.47% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Novocure Ltd (NVCR) Director Sells $241,550.00 in Stock” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://dakotafinancialnews.com/2019/03/15/novocure-ltd-nvcr-director-sells-241550-00-in-stock.html.

About Novocure

Novocure Ltd. operates as an oncology company. It enages in developing its propriety technoclogy, Tumor Treating Fields, which uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumor growth, and causing affected cancer cells to die. The company was founded by Yoram Palti in 2000 and is headquartered in St.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply